2025-02-22 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

This report analyzes Eli Lilly and Co (LLY), a leading pharmaceutical company, based on the provided data.

**1. Performance Comparison and Alpha/Beta Analysis:**

LLY's cumulative return (636.78%) significantly outperforms the S&P 500 (VOO) cumulative return (118.31%).  The difference is substantial (518.5%), placing it at the 82.4th percentile of the historical range of the difference between LLY and VOO returns.

The provided Alpha/Beta analysis shows consistently high CAGR (Compound Annual Growth Rate) figures, indicating strong growth over the analyzed periods.  Alpha values are generally positive, suggesting outperformance relative to the market, especially in recent years.  The increasing Beta values reflect increasing market sensitivity. The substantial increase in market capitalization (Cap(B)) further illustrates the company's impressive growth.  It's important to note that past performance is not indicative of future results.

**2. Recent Price Movement:**

LLY's closing price is $873.68.  The stock shows a recent upward trend:

* **5-day moving average:** $863.06
* **20-day moving average:** $842.92
* **60-day moving average:** $801.40

The price is above all three moving averages, suggesting a bullish momentum.  The small positive change from the previous close (0.06%) indicates a relatively stable, slightly upward movement recently.


**3. Technical Indicators and Expected Return:**

* **RSI (71.16):**  Approaching overbought territory, suggesting potential short-term correction.
* **PPO (0.11):** Positive, indicating bullish momentum.
* **Relative Strength (20-day):** Shows a recent positive change (+0.8), confirming the short-term upward trend.
* **Expected Return (94.2%):**  This represents a significant potential outperformance compared to the S&P 500 over the long term (2+ years) assuming the current trajectory continues.  It's crucial to remember this is a projected value and not guaranteed.

**4. Recent Earnings Analysis:**

The earnings data shows some volatility:

| Date       | EPS    | Revenue       |
|------------|--------|---------------|
| 2024-10-30 | $1.08  | $11.44B       |
| 2024-08-08 | $3.29  | $11.30B       |
| 2024-04-30 | $2.49  | $8.77B        |
| 2023-11-02 | -$0.06 | $9.50B        |
| 2024-10-30 | -$0.06 | $9.50B        | *(Duplicate entry, likely a data error)*


Revenue generally remains stable to slightly increasing. EPS shows fluctuation, requiring further investigation to understand the underlying reasons for the variation.  The duplicate entry for October 30th needs clarification.

**5. Financial Information:**

The financial data exhibits strong revenue and profitability:

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |
| 2023-12-31 | $9.35B    | 80.88%        |

**Capital and Profitability:**

| Quarter | Equity     | ROE           |
|---------|------------|---------------|
| 2024-12-31 | $14.19B   | 31.07%        |
| 2024-09-30 | $14.24B   | 6.81%         |
| 2024-06-30 | $13.56B   | 21.88%        |
| 2024-03-31 | $12.81B   | 17.51%        |
| 2023-12-31 | $10.77B   | 20.33%        |

Revenue shows consistent growth. Profit margins remain high and stable. ROE fluctuates but generally indicates strong profitability.


**6. Overall Conclusion:**

LLY demonstrates exceptional performance compared to the S&P 500, showing strong growth and profitability.  Technical indicators suggest a bullish short-term trend, although RSI is nearing overbought levels. The high expected return is promising, but investors should consider the inherent risks associated with equity investments.  Further investigation into the inconsistencies in EPS data and a deeper analysis of the company's underlying fundamentals and future prospects are recommended before making any investment decisions.  Remember that this analysis is based on the limited data provided and doesn't constitute financial advice.
